- Conditions
- Moderate or Severe Submental Fullness
- Interventions
- Deoxycholic Acid Injection, Placebo, Cold Compress, Lidocaine / Epinephrine, Loratadine, Ibuprofen, Compression Chin Strap
- Drug · Other
- Lead sponsor
- Kythera Biopharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Subcutaneous Fat
- Interventions
- CBL-514 injection, CBL-A1 Injection, CBL-A2 Injection, 0.9% Sodium Chloride
- Drug
- Lead sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Submental Fat
- Interventions
- RZL-012, Placebo
- Drug
- Lead sponsor
- Raziel Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Rhinosinusitis, Nasal Polyps
- Interventions
- Xolair placebo, Xolair (omalizumab)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Warts
- Interventions
- Human Papillomavirus 9-valent Vaccine, Recombinant, Normal Saline
- Biological · Other
- Lead sponsor
- Western Institute for Veterans Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Salt Lake City, Utah
- Conditions
- Schizophrenia
- Interventions
- Placebo, Paliperidone Palmitate
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 414 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Cerritos, California • Santa Ana, California + 15 more
- Conditions
- Raynaud's Disease
- Interventions
- onabotulinum toxin type-A
- Drug
- Lead sponsor
- Southern Illinois University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Springfield, Illinois
- Conditions
- Healthy
- Interventions
- Ad26.Mos.HIV, Ad26.Mos4.HIV, Clade C gp140, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more
- Conditions
- Melanoma, Metastases
- Interventions
- MDX-010 (anti-CTLA4) monoclonal antibody, MDX-1379 (gp100) Melanoma Peptide Vaccine
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,783 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 110
- States / cities
- Tucson, Arizona • Duarte, California • Encinitas, California + 78 more
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab, Placebo
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 58
- States / cities
- Scottsdale, Arizona • Bryant, Arkansas • Rogers, Arkansas + 51 more
- Conditions
- HIV Infections
- Interventions
- Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL, Topical Non-steroidal anti-inflammatory drug (NSAID), Topical steroid, Topical NSAID placebo, Recombinant human hyaluronidase PH20 (rHuPH20), Topical steroid placebo
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 4
- States / cities
- Orlando, Florida • Las Vegas, Nevada • Berlin, New Jersey + 1 more
- Conditions
- Dercum's Disease Lipomas
- Interventions
- RZL-012, Vehicle
- Drug
- Lead sponsor
- Raziel Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
- Interventions
- Certolizumab Pegol, Placebo
- Biological · Other
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more
- Conditions
- HIV Infections
- Interventions
- PENNVAX®-GP HIV-1 DNA vaccine, Interleukin-12 (IL-12) DNA adjuvant, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Decatur, Georgia • Rochester, New York • Nashville, Tennessee + 1 more
- Conditions
- Moderate to Severe Palmoplantar Psoriasis
- Interventions
- secukinumab 150 mg, secukinumab 300 mg, Placebo
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Indianapolis, Indiana + 5 more
- Conditions
- HIV Infections
- Interventions
- GSK3732394, Placebo
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Osteoarthritis, Articular Cartilage, Musculoskeletal Disorders
- Interventions
- Platelet-Rich Plasma (PRP) Injections, Centrifuge, Control saline injection
- Drug · Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Coronavirus, Covid19
- Interventions
- bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,044 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 207
- States / cities
- Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
- Conditions
- Influenza, Vaccine
- Interventions
- cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS)
- Biological
- Lead sponsor
- PATH
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Cincinnati, Ohio
- Conditions
- Hereditary Periodic Fevers
- Interventions
- Canakinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Ann Arbor, Michigan • Cleveland, Ohio
- Conditions
- Paroxysmal Atrial Fibrillation, Indications for CABG
- Interventions
- botulinum toxin injection, 0.9% normal saline injection, Implantable loop recorder
- Biological · Device
- Lead sponsor
- Meshalkin Research Institute of Pathology of Circulation
- Network
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- 0.5mg AZ-010; placebo, 1mg AZ-010, 3mg AZ-010, AZ-010 1mg, IV Granisetron 1mg, Placebo
- Combination Product · Drug · Other
- Lead sponsor
- Nova Pneuma Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- SARS-CoV-2 Infection
- Interventions
- 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant), Sodium chloride, USP, for injection (0.9% NaCl), 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
- Biological · Drug
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Alcohol Dependence, Alcohol Use Disorder
- Interventions
- XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York